Clinical and Prognostic Implications of an Alternative Splicing-related Risk Model Based on TP53 Status in Breast Cancer
We have demonstrated differential transcriptomic splicing events between TP53 mutant and wild-type cases of breast cancer, establishing an effective prognostic risk model based on AS events. These findings provide new insights that may aid in understanding the biological behavior of breast cancer and potentially in optimizing treatment strategies for breast cancer.
Authors
- Zhoujie Ye (ORCID: https://orcid.org/0000-0003-2026-9333)
- Liping Zhou (ORCID: https://orcid.org/0000-0003-2353-6134)
- Yujia Chen (ORCID: https://orcid.org/0009-0004-1950-1064)
- Xinrui Wang (ORCID: https://orcid.org/0000-0002-3085-5697)
Institutions
- Fujian Medical University (CN)
Publication Details
- Journal
- Current Pharmaceutical Biotechnology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.2174/0113892010283176240212073417
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Natural Science Foundation of Fujian Province